4 unchanged sentences
333-257436), as amended, filed in connection with our IPO.
−Removed: Our IPO closed on July 20, 2021, and we issued and sold 21,562,500 shares of our common stock at a price to the public of $16.00 per share, which included the exercise in full of the underwriters’
−Removed: option to purchase additional shares.
+Added: Our IPO closed on July 20, 2021, and we issued and sold 21,562,500 shares of our common stock at a price to the public of $16.00 per share, which included the exercise in full of the underwriters’ option to purchase additional shares.
We received gross proceeds from our IPO of $345.0 million, before deducting underwriting discounts and commissions of $24.2 million and offering costs of $3.8 million.
4 unchanged sentences
No offering costs were paid or are payable, directly or indirectly, to our directors or officers, to persons owning 10% or more of any class of our equity securities or to any of our affiliates.
−Removed: As of September 30, 2023, we have used approximately $268.4 million of the proceeds from our IPO for general corporate purposes, including to fund the research and development of ERAS-007, ERAS-601 and our other RAS/MAPK pathway-focused pipeline programs.
+Added: As of March 31, 2024, we have used all of the proceeds from our IPO for general corporate purposes, including to fund the research and development of naporafenib, ERAS-007, ERAS-801 and our other RAS/MAPK pathway-focused pipeline programs.
There has been no material change in the planned use of such proceeds from that described in the prospectus for our IPO.
4 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.